Does scopolamine improve attention more than placebo in healthy volunteers and what does this tell us about mechanisms of attention?

Does scopolamine improve selective attention and cognition more than placebo in healthy male volunteers?

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000603910

Enrollment

Registered

2011-06-10

Start date

2011-06-20

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Attentional processing is a cognitive skill that allows us to interpret and act in our environment. Although this skill is important, little is understoond about the neurochemical processes that are important to attention. This study will allow us to assess the importance of different brain chemicals in contributing to selective attention function.

Interventions

A single dose of scopolamine (0.8mg contained in one capsule) (1-2 week washout between conditions)

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

Male

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

Healthy volunteers Aged 18-40 years Male

Exclusion criteria

Current psychiatric or neurological diagnosis Current use of psychotropic medication Current use of cholinergic or anticholinergic medication Medical condition in which scopolamine is contraindicated

Outcome results